Rakovina Therapeutics Inc. (RKV.V)

0.1600 0.0000 (0.00%) At close: 01:15PM EDT

Rakovina Therapeutics Inc.

1008 Beach Avenue
Suite 105
Vancouver, BC V6E 1T7
Canada

https://www.rakovinatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A.	Exec. Chairman	N/A	N/A	1968
Dr. Mads Daugaard	Pres & Chief Scientific Officer	N/A	N/A	N/A
Mr. David Hyman CA, CBV	CFO & Corp. Sec.	N/A	N/A	1973
Dr. John Langlands Ph.D.	Chief Operating Officer	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Rakovina Therapeutics Inc., a biopharmaceutical company, focuses on development of cancer therapies based on novel DNA-damage response technologies. The company's lead pipeline products include kt-2000, the next generation oral targeted small molecule PARP inhibitors; kt-3000, a class of small-molecule drug candidates to overcome and prevent resistance to treatment with first generation DDRi; and kt-4000 to cause targeted DNA-damage to a tumor cell's DNA while simultaneously inhibiting the tumor's DNA damage response. Rakovina Therapeutics was founded in 2020 and is headquartered in Vancouver, Canada.

Corporate Governance

Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.